B+
Bull case
0%
Probability
Target price
$34.00
Analysis reference price unavailable
Analysis 2026-06-30 · RankAlpha Sentiment Codex
ARQT
Arcutis BiotherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The cleanest bull case is that Arcutis is transitioning from biotech to scaled dermatology commercial company: ZORYVE revenue grew 65% year over year in Q1, the company sustained positive operating cash flow, maintained $480M-$495M 2026 revenue guidance, and has now added another pediatric label expansion to deepen franchise breadth [#PR-EARNINGS-2026-05-07] [#IR-2026-06-29].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +3.4.
What can break
Commercial investment is still elevated: Q1 SG&A rose year over year due to compensation, personnel, and higher sales and marketing spending tied to ongoing launch expansion [#PR-EARNINGS-2026-05-07].
Momentum
14
Value
57
Sentiment
81
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $28.00 · Bull $34.00 · Bear $20.00Analysis 2026-06-30; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-30 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $36.88
Why
Momentum14 · Δ7d +2.9
Value57 · Δ7d -0.0
Sentiment81 · Δ7d +3.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +3.4.
Contradictions & invalidation
- • Commercial investment is still elevated: Q1 SG&A rose year over year due to compensation, personnel, and higher sales and marketing spending tied to ongoing launch expansion [#PR-EARNINGS-2026-05-07].
- • Pipeline and regulatory timing remain execution risks, including conversion of pediatric and new-indication programs into approvable and commercially relevant assets.
- • The bear case is that near-term upside may already reflect good regulatory momentum while fundamentals still need to prove durability: Q1 revenue fell 17% sequentially, SG&A and R&D stepped up with commercialization and ARQ-234 costs, and the story remains heavily dependent on ZORYVE execution plus pipeline milestones that are still months away [#PR-EARNINGS-2026-05-07].
Catalyst clock
2026-06-29
FDA approved pediatric plaque-psoriasis label expansion for ZORYVE cream 0.3%
Lead driver: Sentiment · See AI snapshot
Momentum
14
9% active weight
Current posture
7d trendImproving
Δ7d
+2.9
Δ21d
-18.5
Value
57
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+8.0
Sentiment
81
62% active weight
Current posture
7d trendImproving
Δ7d
+3.4
Δ21d
+13.6
Why this grade
Composite grade B. Momentum 14.3 / Value 56.7 / Sentiment 81.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-30. Scenario method
Most likely
B
Base case
0%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-06-30 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-06-30 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$3.22B
Beta
1.71
Shares Out
125.69M
P/E (TTM) · Derived
-201.8
P/S (TTM)
11.64
P/FCF (TTM) · Derived
88.62
Rev YoY
+59.3%
EPS YoY
-188.2%
Gross Margin
+91.1%
Op Margin
+7.4%
Net Debt
-$107.07M
Current Ratio
2.92
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data